DK1057480T3 - Transdermal östrogen-agonist-antagonist-behandling - Google Patents

Transdermal östrogen-agonist-antagonist-behandling

Info

Publication number
DK1057480T3
DK1057480T3 DK00304611T DK00304611T DK1057480T3 DK 1057480 T3 DK1057480 T3 DK 1057480T3 DK 00304611 T DK00304611 T DK 00304611T DK 00304611 T DK00304611 T DK 00304611T DK 1057480 T3 DK1057480 T3 DK 1057480T3
Authority
DK
Denmark
Prior art keywords
agonist
antagonist treatment
transdermal estrogen
estrogen
transdermal
Prior art date
Application number
DK00304611T
Other languages
English (en)
Inventor
Silva-Jardine Paul Andrew Da
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1057480T3 publication Critical patent/DK1057480T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
DK00304611T 1999-06-01 2000-05-30 Transdermal östrogen-agonist-antagonist-behandling DK1057480T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13716499P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
DK1057480T3 true DK1057480T3 (da) 2004-11-08

Family

ID=22476088

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00304611T DK1057480T3 (da) 1999-06-01 2000-05-30 Transdermal östrogen-agonist-antagonist-behandling

Country Status (16)

Country Link
EP (1) EP1057480B1 (da)
JP (1) JP2001002588A (da)
KR (1) KR20010029770A (da)
AT (1) ATE269698T1 (da)
AU (1) AU3781000A (da)
CA (1) CA2310272A1 (da)
CO (1) CO5170459A1 (da)
DE (1) DE60011710T2 (da)
DK (1) DK1057480T3 (da)
ES (1) ES2220346T3 (da)
HU (1) HUP0002085A3 (da)
IL (1) IL136376A0 (da)
NZ (1) NZ504868A (da)
PE (1) PE20010207A1 (da)
PT (1) PT1057480E (da)
ZA (1) ZA200002693B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CA2380769A1 (en) * 2000-06-01 2001-12-06 Watson Pharmaceuticals, Inc. Transdermal delivery of lasofoxifene
US20140067048A1 (en) 2012-09-06 2014-03-06 Edwards Lifesciences Corporation Heart Valve Sealing Devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment

Also Published As

Publication number Publication date
KR20010029770A (ko) 2001-04-16
EP1057480B1 (en) 2004-06-23
PT1057480E (pt) 2004-10-29
HUP0002085A2 (en) 2001-03-28
ES2220346T3 (es) 2004-12-16
HUP0002085A3 (en) 2002-09-30
CA2310272A1 (en) 2000-12-01
NZ504868A (en) 2001-09-28
IL136376A0 (en) 2001-06-14
DE60011710D1 (de) 2004-07-29
HU0002085D0 (en) 2000-08-28
AU3781000A (en) 2000-12-07
ATE269698T1 (de) 2004-07-15
JP2001002588A (ja) 2001-01-09
ZA200002693B (en) 2001-11-30
EP1057480A2 (en) 2000-12-06
EP1057480A3 (en) 2002-01-09
CO5170459A1 (es) 2002-06-27
PE20010207A1 (es) 2001-02-28
DE60011710T2 (de) 2005-06-30

Similar Documents

Publication Publication Date Title
DE69828042D1 (de) Verfahren und zusammensetzung zur behandlung von krebs
BRPI9914164B8 (pt) compostos de 3-ciano quinolina
ATE399547T1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia
DE60013266D1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
FI20011457A (fi) Yhdistetty poistokaasun-painolastiveden käsittelyjärjestely ja menetelmä painolastiveden käsittelemiseksi
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
PT938326E (pt) Fosfopeptidos de sintese para o tratamento de doencas dos ossos
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ES2191475T3 (es) Conjugados de prostaglandina para el tratamiento o prevencion de enfermedades oseas.
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
DE60009665D1 (de) Zusammensetzungen zur behandlung von entzündungsreaktionen
FI991220A (fi) Menetelmä massan käsittelemiseksi
ATE288303T1 (de) Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel
ATE493125T1 (de) Carbamatverbindungen zur behandlung von schmerz
DK1057480T3 (da) Transdermal östrogen-agonist-antagonist-behandling
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
DE69931963D1 (de) Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
DE69816244D1 (de) Verwendung von 2-Aryl-3-aroylbenzo(b)thiophene zur Behandlung des Oestrogenenthaltungssyndroms
NO20014222L (no) Fremgangsmåte for behandling av COPD
DK1131073T3 (da) Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
ATE307871T1 (de) Verfahren zur behandlung von gewebe
DE69928501D1 (de) Mittel zur vorbeugung/behandlung von osteoporose
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids